Clinical Trial Update: CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This update covers a Phase 1/2 trial evaluating CD19-targeted CAR-T cell therapy for lymphoma. The current status is not disclosed in the snippet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• CD19-targeted CAR-T cell therapy

Snippet

Sponsor: Zhejiang University | Conditions: Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN